Ena Soric
Zagreb, 10000, Croatia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Hepatotoxicity Profile of Bortezomib-Containing Regimens for First-Line Multiple Myeloma Treatment.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 01, 2026
Multinational Attitudes Toward AI in Health Care and Diagnostics Among Hospital Patients.
Journal: JAMA network open
Published: June 10, 2025
Extreme Thrombocytosis in Patients with Overt Myelofibrosis and Its Clinical Associations.
Journal: Cancers
Published: March 12, 2025
Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis.
Journal: Life (Basel, Switzerland)
Published: March 08, 2024
Secondary polycythemia in acutely ill COVID-19 patients is associated with higher mortality but not markedly higher thrombotic risk.
Journal: Scandinavian journal of clinical and laboratory investigation
Published: February 28, 2024
Heavily pretreated patient with nodal marginal zone lymphoma successfully treated with mosunetuzumab.
Journal: Annals of hematology
Published: September 18, 2023
Estimated plasma volume status in COVID-19 patients and its relation to comorbidities and clinical outcomes.
Journal: Journal of thrombosis and thrombolysis
Published: August 05, 2023
Higher JAK2 V617F mutant allele burden in patients with chronic myeloproliferative neoplasms is associated with a higher prevalence of chronic kidney disease and unfavorable dynamics of kidney function over time.
Journal: Annals of hematology
Published: March 12, 2023
Palpable spleen size is differently prognostic in primary and secondary myelofibrosis.
Journal: Leukemia & lymphoma
Published: February 17, 2023
Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis.
Journal: Biochemia medica
Published: October 05, 2022
Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis.
Journal: Leukemia research
Published: June 13, 2022
Last Updated: 09/26/2026